42 Negative correlation between PlGF and Endocan-1 in women with preeclampsia

Introduction: Endocan-1 is a soluble proteoglican specifically expressed in endothelial cells, a biomarker/predictor of vascular endothelial related pathologies, as pre-eclampsia (PE). PlGF is an angiogenic factor, and a marker of placental dysfunction, which is down regulated in women with PE....

Full description

Bibliographic Details
Main Authors: Ribeiro Hentschke, Marta, Mistry, Hiten D., Ercilia Pinheiro da Costa, Bartira, Poli-de-Figueiredo, Carlos Eduardo
Format: Article
Language:English
Published: Elsevier 2016
Online Access:https://eprints.nottingham.ac.uk/54175/
_version_ 1848799022650753024
author Ribeiro Hentschke, Marta
Mistry, Hiten D.
Ercilia Pinheiro da Costa, Bartira
Poli-de-Figueiredo, Carlos Eduardo
author_facet Ribeiro Hentschke, Marta
Mistry, Hiten D.
Ercilia Pinheiro da Costa, Bartira
Poli-de-Figueiredo, Carlos Eduardo
author_sort Ribeiro Hentschke, Marta
building Nottingham Research Data Repository
collection Online Access
description Introduction: Endocan-1 is a soluble proteoglican specifically expressed in endothelial cells, a biomarker/predictor of vascular endothelial related pathologies, as pre-eclampsia (PE). PlGF is an angiogenic factor, and a marker of placental dysfunction, which is down regulated in women with PE. We hypothesized that Endocan-1 and PlGF levels would be negatively correlated in pregnant women with PE. Objectives: To analyse Endocan-1 and PlGF levels in maternal plasma in normotensive and women with PE and test the correlation between the findings in the third trimester of pregnancy. Methods: Endocan-1 and PlGF levels were measured in maternal plasma from normotensive (n= 67) and PE (n= 50) women using MagPlexTH-C microspheres system. Data was analysed by ANCOVA, adjusted for BMI, gestational age and maternal age. To estimate the difference between groups, mean ratio (MR) and confidence interval (CI) of 95% was calculated. Analysis between Endocan-1 levels and PlGF were made by Pearson correlation. The null hypothesis was rejected when p < 0.05. Results: Higher concentrations of Endocan-1 were found in maternal plasma in PE (MR = 1.49; 95% CI: 1.19–1.85,p= 0.001), with a moderate effect size (Cohen’s D = 0.84). When women with superimposed PE and HELLP syndrome were excluded, lower levels of PlGF were found in the PE group (MR = 0.38, 95% CI: 0.15–0.95 p = 0.041). A strong negative correlation between Endocan-1 e PlGF in the entire group (r=-0.605; p < 0.001); as well as in PE group (r=-0.545; p < 0.001) was observed. Conclusion: Endocan-1 levels are increased in patients with PE and are negatively correlated with PlGF levels. These data could be related to hypoxemia and fetal growth restriction (seen by lower PlGF levels), leading to a systemic response in order to find a volumetric compensation; leading to endothelial lesions (seen as the upregulation of Endocan-1). Thus, it is important to analyse angiogenic and proinflamatory molecules concomitantly in women with PE, in order to better understand the disease pathophysiology. In this case, both molecules are strong potentials as specific PE biomarkers.
first_indexed 2025-11-14T20:29:04Z
format Article
id nottingham-54175
institution University of Nottingham Malaysia Campus
institution_category Local University
language English
last_indexed 2025-11-14T20:29:04Z
publishDate 2016
publisher Elsevier
recordtype eprints
repository_type Digital Repository
spelling nottingham-541752018-09-11T10:57:33Z https://eprints.nottingham.ac.uk/54175/ 42 Negative correlation between PlGF and Endocan-1 in women with preeclampsia Ribeiro Hentschke, Marta Mistry, Hiten D. Ercilia Pinheiro da Costa, Bartira Poli-de-Figueiredo, Carlos Eduardo Introduction: Endocan-1 is a soluble proteoglican specifically expressed in endothelial cells, a biomarker/predictor of vascular endothelial related pathologies, as pre-eclampsia (PE). PlGF is an angiogenic factor, and a marker of placental dysfunction, which is down regulated in women with PE. We hypothesized that Endocan-1 and PlGF levels would be negatively correlated in pregnant women with PE. Objectives: To analyse Endocan-1 and PlGF levels in maternal plasma in normotensive and women with PE and test the correlation between the findings in the third trimester of pregnancy. Methods: Endocan-1 and PlGF levels were measured in maternal plasma from normotensive (n= 67) and PE (n= 50) women using MagPlexTH-C microspheres system. Data was analysed by ANCOVA, adjusted for BMI, gestational age and maternal age. To estimate the difference between groups, mean ratio (MR) and confidence interval (CI) of 95% was calculated. Analysis between Endocan-1 levels and PlGF were made by Pearson correlation. The null hypothesis was rejected when p < 0.05. Results: Higher concentrations of Endocan-1 were found in maternal plasma in PE (MR = 1.49; 95% CI: 1.19–1.85,p= 0.001), with a moderate effect size (Cohen’s D = 0.84). When women with superimposed PE and HELLP syndrome were excluded, lower levels of PlGF were found in the PE group (MR = 0.38, 95% CI: 0.15–0.95 p = 0.041). A strong negative correlation between Endocan-1 e PlGF in the entire group (r=-0.605; p < 0.001); as well as in PE group (r=-0.545; p < 0.001) was observed. Conclusion: Endocan-1 levels are increased in patients with PE and are negatively correlated with PlGF levels. These data could be related to hypoxemia and fetal growth restriction (seen by lower PlGF levels), leading to a systemic response in order to find a volumetric compensation; leading to endothelial lesions (seen as the upregulation of Endocan-1). Thus, it is important to analyse angiogenic and proinflamatory molecules concomitantly in women with PE, in order to better understand the disease pathophysiology. In this case, both molecules are strong potentials as specific PE biomarkers. Elsevier 2016-07-20 Article PeerReviewed application/pdf en cc_by_nc_nd https://eprints.nottingham.ac.uk/54175/1/RBGO-2018-0040.R1-Original-article_MH%20%28002%29.pdf Ribeiro Hentschke, Marta, Mistry, Hiten D., Ercilia Pinheiro da Costa, Bartira and Poli-de-Figueiredo, Carlos Eduardo (2016) 42 Negative correlation between PlGF and Endocan-1 in women with preeclampsia. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health, 6 (3). p. 157. ISSN 2210-7789 http://dx.doi.org/10.1016/j.preghy.2016.08.043 10.1016/j.preghy.2016.08.043 10.1016/j.preghy.2016.08.043 10.1016/j.preghy.2016.08.043
spellingShingle Ribeiro Hentschke, Marta
Mistry, Hiten D.
Ercilia Pinheiro da Costa, Bartira
Poli-de-Figueiredo, Carlos Eduardo
42 Negative correlation between PlGF and Endocan-1 in women with preeclampsia
title 42 Negative correlation between PlGF and Endocan-1 in women with preeclampsia
title_full 42 Negative correlation between PlGF and Endocan-1 in women with preeclampsia
title_fullStr 42 Negative correlation between PlGF and Endocan-1 in women with preeclampsia
title_full_unstemmed 42 Negative correlation between PlGF and Endocan-1 in women with preeclampsia
title_short 42 Negative correlation between PlGF and Endocan-1 in women with preeclampsia
title_sort 42 negative correlation between plgf and endocan-1 in women with preeclampsia
url https://eprints.nottingham.ac.uk/54175/
https://eprints.nottingham.ac.uk/54175/
https://eprints.nottingham.ac.uk/54175/